Chemotherapy Induced Nausea and Vomiting Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Chemotherapy induced nausea and vomiting pipeline market research report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Nausea and Vomiting, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Nausea and Vomiting and features dormant and discontinued projects.
Key Targets in the Chemotherapy Induced Nausea and Vomiting Pipeline Market
The key targets in the chemotherapy induced nausea and vomiting pipeline market are 5-Hydroxytryptamine Receptor 3, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Substance P Receptor, Cannabinoid Receptor, D2 Dopamine Receptor, Glucocorticoid Receptor, 5-Hydroxytryptamine Receptor 2A, and D3 Dopamine Receptor.
Chemotherapy Induced Nausea and Vomiting Pipeline Market, by Targets
For more target insights, download a free report sample
Key MoA in the Chemotherapy Induced Nausea and Vomiting Pipeline Market
The key MoA in the chemotherapy induced nausea and vomiting pipeline market are 5-Hydroxytryptamine Receptor 3 Antagonist, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Substance P Receptor Antagonist, Cannabinoid Receptor Agonist, D2 Dopamine Receptor Antagonist, Glucocorticoid Receptor Agonist, 5-Hydroxytryptamine Receptor 2A Antagonist, and D3 Dopamine Receptor Antagonist.
Chemotherapy Induced Nausea and Vomiting Pipeline Market, by MoA
For more MoA insights, download a free report sample
Key RoA in the Chemotherapy Induced Nausea and Vomiting Pipeline Market
The key RoA in the chemotherapy induced nausea and vomiting pipeline market are oral, intravenous, inhalational, buccal, transdermal, nasal, parenteral, subcutaneous, sublingual, suppository, and transmucosal. Oral has the highest number of pipeline markets.
Chemotherapy Induced Nausea and Vomiting Pipeline Market, by RoA
For more RoA insights, download a free report sample
Key Molecule Type in the Chemotherapy Induced Nausea and Vomiting Pipeline Market
The key molecule type in the chemotherapy induced nausea and vomiting pipeline market is small molecule.
Key Companies in the Chemotherapy Induced Nausea and Vomiting Pipeline Market
The key companies in the chemotherapy induced nausea and vomiting pipeline market are Helsinn Group, Luxena Pharmaceuticals Inc, AcuCort AB, Aphios Corp, IntelGenx Corp, Acacia Pharma Ltd, Amzell BV, Arovella Therapeutics Ltd, and Athenex Inc.
Chemotherapy Induced Nausea and Vomiting Pipeline Market, by Companies
To know about more key companies, download a free report sample
Market report overview
| Key targets | 5-Hydroxytryptamine Receptor 3, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Substance P Receptor, Cannabinoid Receptor, D2 Dopamine Receptor, Glucocorticoid Receptor, 5-Hydroxytryptamine Receptor 2A, and D3 Dopamine Receptor |
| Key MoA | 5-Hydroxytryptamine Receptor 3 Antagonist, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Substance P Receptor Antagonist, Cannabinoid Receptor Agonist, D2 Dopamine Receptor Antagonist, Glucocorticoid Receptor Agonist, 5-Hydroxytryptamine Receptor 2A Antagonist, and D3 Dopamine Receptor Antagonist |
| Key RoA | Oral, Intravenous, Inhalational, Buccal, Transdermal, Nasal, Parenteral, Subcutaneous, Sublingual, Suppository, and Transmucosal |
| Key molecule type | Small Molecule |
| Key companies | Helsinn Group, Luxena Pharmaceuticals Inc, AcuCort AB, Aphios Corp, IntelGenx Corp, Acacia Pharma Ltd, Amzell BV, Arovella Therapeutics Ltd, and Athenex Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Nausea and Vomiting (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Nausea and Vomiting (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chemotherapy Induced Nausea and Vomiting (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chemotherapy Induced Nausea and Vomiting (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Nausea and Vomiting (Toxicology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Nausea and Vomiting (Toxicology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Nausea and Vomiting (Toxicology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
AcuCort AB
Amzell BV
Aphios Corp
Arovella Therapeutics Ltd
Athenex Inc
Axim Biotechnologies Inc
Benuvia Therapeutics Inc
Bionorica SE
Camurus AB
Daewoong Pharmaceutical Co Ltd
Ethicann Pharmaceuticals Inc
Helsinn Group
Hoverink Biotechnologies Inc
IntelGenx Corp
Jiangsu Hengrui Medicine Co Ltd
LipoSeuticals Inc
LP Pharmaceutical (Xiamen) Co Ltd
Luxena Pharmaceuticals Inc
MannKind Corp
Senzer Ltd
Shackelford Pharma Inc
Skye Bioscience Inc
SoluBest Ltd
Starton Therapeutics Inc
Yichang Humanwell Pharmaceutical Co Ltd
Table of Contents
Frequently asked questions
-
What are the key targets in the chemotherapy induced nausea and vomiting pipeline market?
The key targets in the chemotherapy induced nausea and vomiting pipeline market are 5-Hydroxytryptamine Receptor 3, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Substance P Receptor, Cannabinoid Receptor, D2 Dopamine Receptor, Glucocorticoid Receptor, 5-Hydroxytryptamine Receptor 2A, and D3 Dopamine Receptor.
-
What are the key MoA in the chemotherapy induced nausea and vomiting pipeline market?
The key MoA in the chemotherapy induced nausea and vomiting pipeline market are 5-Hydroxytryptamine Receptor 3 Antagonist, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Substance P Receptor Antagonist, Cannabinoid Receptor Agonist, D2 Dopamine Receptor Antagonist, Glucocorticoid Receptor Agonist, 5-Hydroxytryptamine Receptor 2A Antagonist, and D3 Dopamine Receptor Antagonist.
-
What are the key RoA in the chemotherapy induced nausea and vomiting pipeline market?
The key RoA in the chemotherapy induced nausea and vomiting pipeline market are oral, intravenous, inhalational, buccal, transdermal, nasal, parenteral, subcutaneous, sublingual, suppository, and transmucosal.
-
What are the key molecule type in the chemotherapy induced nausea and vomiting pipeline market?
The key molecule type in the chemotherapy induced nausea and vomiting pipeline market is small molecule.
-
What are the key companies in the chemotherapy induced nausea and vomiting pipeline market?
The key companies in the chemotherapy induced nausea and vomiting pipeline market are Helsinn Group, Luxena Pharmaceuticals Inc, AcuCort AB, Aphios Corp, IntelGenx Corp, Acacia Pharma Ltd, Amzell BV, Arovella Therapeutics Ltd, and Athenex Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Other Diseases reports